FDA Approves GlaxoSmithKline' Lamictal XR For Epilepsy Treatment

Anonymous User | Login

FDA Approves GlaxoSmithKline' Lamictal XR For Epilepsy Treatment

Published: 02-Jun-2009

GlaxoSmithKline has announced that the US Food and Drug Administration (FDA) has approved Lamictal XR (lamotrigine) Extended-Release tablets as once-a-day add-on therapy for epilepsy patients with partial onset seizures.

Lamictal XR is approved as an add-on therapy for adult and adolescent patients who experience partial seizures with or without secondary generalization.

Lamictal XR reduced the frequency of partial seizures during a 19-week study. More patients who took Lamictal XR had a significant reduction in seizure frequency, as compared to placebo.

Dean Naritoku, Professor and Chairman of neurology, said: Many patients require multiple doses of one or more medications to control their epilepsy, which makes taking their medicines even more challenging.”

“Lamictal XR is an important once-daily advance for patients with epilepsy who still experience seizures while taking their current therapy, he added.

Sanofi Receives $190m For New Influenza A(H1N1) Virus Vaccine

Sanofi Pasteur (Sanofi), a part of sanofi-aventis Group, has received an initial order of $190 million from the US Department of Health and Human Services (HHS) to commen ...

US To Grant $800m To Pharma Majors For Swine Flu Vaccine

The US government has announced plans to invest around $1 billion to support pharmaceutical companies for the development of swine flu vaccine. The US department of Healt ...

Xyntha' Sales Exceed BDI Pharma’s Q1 Projections

BDI Pharma, a wholesaler of biopharmaceutical products, has posted strong growth in sales of Wyeth’s XYNTHA Antihemophilic Factor (Recombinant) for the first quarter of 2 ...

Cancer Research UK, GSK To Jointly Develop Anti-cancer Drug

Cancer Research UK and Cancer Research Technology (CRT) will commence the phase I clinical trial of GlaxoSmithKline's (GSK) anti-cancer drug 1070916A, an aurora kinase in ...

Glaxo Provides 50m Pandemic Vaccines

In order to support governments and health authorities around the world to respond to the outbreak of global flu, British pharmaceutical giant GlaxoSmithKline has offered ...

US States Join Medicaid’s Lawsuits Against Wyeth

The US Justice Department has joined forces with 16 states in a legal fight against Wyeth, alleging that the drug maker has failed to reimburse hundreds of millions of do ...

Glaxo to make Swine-Flu Vaccine

GlaxoSmithKline (Glaxo) is planning to produce a vaccine against the current strain of the A/H1N1 virus, responsible for the outbreak of swine-flu worldwide. Glaxo is try ...

Bristol-Myers Posts Net Earnings Of $638 Million In Q1 2009

Bristol-Myers Squibb Company (Bristol-Myers), an in vitro diagnostics company, has reported net sales of $5.01 billion for the first quarter of 2009, compared with the ne ...

Abbott Reports Net Earnings Of $1.4 Billion For Q1 2009

Abbott Laboratories (Abbott), a US-based health care company, has reported net sales of $6.7 billion for the first quarter of 2009, down 0.7%, compared with the net sales ...

Bristol-Myers Squibb Announces Executive Changes

Bristol-Myers Squibb Company (Bristol-Myers), a in vitro diagnostics company, announced organizational changes. Lamberto Andreotti, Elliott Sigal, and Jean-Marc Huet will ...

Network Sites

Contract Research Clinical Trials Contract Services Drug Delivery Drug Discovery & Development OTC Regulatory Affairs Process and Production IT and Software Laboratory Instrumentation Manufacturing Fine & Specialty Chemicals Medical Devices Business Review Inward Investment Packaging

Mail sent successfully

Tell your friend about this article

Please enter a valid email address

Please enter your name

Please enter the mail body

Your Name: *

Your Email: *

Friend's Email: *

Email Body: *: I thought you would be interested in this article : http://drugdelivery.pharmaceutical-business-review.com/news/fda_approves_glaxosmithkline_lamictal_xr_for_epilepsy_treatment_090602/

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

ADAPT Localization

The Translation and Localization Specialists ...

Aveva Drug Delivery Systems

Innovative Drug Delivery Solutions ...

Capsugel

Providing Innovative Doasge Forms and Solutions to Health Care Customers ...

Geodis Wilson

Global Pharmaceutical Freight Management Services ...

Kuecept

Concept Formulation Design ...

Medilingua Translations

The Medical Translation Specialists ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Related Companies

AstraZeneca PLC

AstraZeneca PLC (AstraZeneca) is a leading pharmaceuticals company engaged in the desig ...

Schering-Plough Corporation

Schering-Plough Corporation (Schering-Plough) is a pharmaceutical company focused on di ...

Amgen Inc.

Amgen Inc. (Amgen) is a biotechnology company that is focused on the discovery, develo ...

Abbott Laboratories

Abbott Laboratories (Abbott) is a global health care company. It is principally engaged ...

GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a is a United Kingdom-based pharmaceutical, biological, a ...

Suppliers Product News

Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres Tts®

Par to begin shipping clonidine TDS in the near future.

Aveva's Partner Receives FDA Approval for Onsolis

FDA approves opioid pain reliever with required risk reduction plan.

Teva Announces FDA Approval and Commercial Launch of Fentanyl Transdermal System

Kuecept and The School of Pharmacy Agree Key Drug Delivery Licensing

Kuecept Ltd and The School of Pharmacy, University of London agree key drug delivery licensing deals to facilitate the development of low solubility, poorly bioavailable compounds.

Synectix Pharmaceutical Solutions Now Called Kuecept

Synectix Pharmaceutical Solutions Ltd, the speciality drug development company, announced today that effective immediately, the company has changed its name to Kuecept Ltd.

Quality Control in Medical Translation

Various methods are available to ensure the quality of medical translations – but some are more effective than others.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

FDA Approves GlaxoSmithKline' Lamictal XR For Epilepsy Treatment

Published: 02-Jun-2009

GlaxoSmithKline has announced that the US Food and Drug Administration (FDA) has approved Lamictal XR (lamotrigine) Extended-Release tablets as once-a-day add-on therapy for epilepsy patients with partial onset seizures.

Related Articles

Network Sites

Mail sent successfully

Tell your friend about this article

Suppliers To This Sector

The Translation and Localization Specialists ...

Innovative Drug Delivery Solutions ...

Providing Innovative Doasge Forms and Solutions to Health Care Customers ...

Global Pharmaceutical Freight Management Services ...

Concept Formulation Design ...

The Medical Translation Specialists ...

White Papers

Related Companies

AstraZeneca PLC (AstraZeneca) is a leading pharmaceuticals company engaged in the desig ...

Schering-Plough Corporation (Schering-Plough) is a pharmaceutical company focused on di ...

Amgen Inc. (Amgen) is a biotechnology company that is focused on the discovery, develo ...

Abbott Laboratories (Abbott) is a global health care company. It is principally engaged ...

GlaxoSmithKline plc (GSK) is a is a United Kingdom-based pharmaceutical, biological, a ...

Suppliers Product News

Par to begin shipping clonidine TDS in the near future.

FDA approves opioid pain reliever with required risk reduction plan.

Kuecept Ltd and The School of Pharmacy, University of London agree key drug delivery licensing deals to facilitate the development of low solubility, poorly bioavailable compounds.

Synectix Pharmaceutical Solutions Ltd, the speciality drug development company, announced today that effective immediately, the company has changed its name to Kuecept Ltd.

Various methods are available to ensure the quality of medical translations – but some are more effective than others.

Free Newsletter Sign-up

Business Review Sites: